Madrigal Pharmaceuticals (MDGL) Competitors $314.39 -12.71 (-3.89%) Closing price 04:00 PM EasternExtended Trading$299.69 -14.70 (-4.68%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDGL vs. BIIB, UTHR, BMRN, INCY, NBIX, EXEL, EXAS, HALO, RGEN, and ALKSShould you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Alkermes (ALKS). These companies are all part of the "biotechnology" industry. Madrigal Pharmaceuticals vs. Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Exact Sciences Halozyme Therapeutics Repligen Alkermes Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Does the media favor MDGL or BIIB? In the previous week, Biogen had 25 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 32 mentions for Biogen and 7 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.25 beat Biogen's score of 1.14 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 22 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in MDGL or BIIB? 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is MDGL or BIIB more profitable? Biogen has a net margin of 16.87% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Biogen's return on equity of 14.98% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal PharmaceuticalsN/A -71.78% -53.25% Biogen 16.87%14.98%8.76% Do analysts recommend MDGL or BIIB? Madrigal Pharmaceuticals currently has a consensus price target of $378.44, suggesting a potential upside of 20.37%. Biogen has a consensus price target of $213.33, suggesting a potential upside of 73.47%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80Biogen 0 Sell rating(s) 18 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.42 Does the MarketBeat Community favor MDGL or BIIB? Biogen received 1354 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 71.44% of users gave Biogen an outperform vote while only 67.94% of users gave Madrigal Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMadrigal PharmaceuticalsOutperform Votes46267.94% Underperform Votes21832.06% BiogenOutperform Votes181671.44% Underperform Votes72628.56% Which has more volatility and risk, MDGL or BIIB? Madrigal Pharmaceuticals has a beta of -0.68, suggesting that its stock price is 168% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Which has higher valuation & earnings, MDGL or BIIB? Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal Pharmaceuticals$180.13M38.54-$373.63M-$22.11-14.22Biogen$9.68B1.86$1.63B$11.1910.99 SummaryBiogen beats Madrigal Pharmaceuticals on 13 of the 19 factors compared between the two stocks. Remove Ads Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDGL vs. The Competition Export to ExcelMetricMadrigal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.94B$6.32B$5.24B$7.07BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-12.546.7221.2017.47Price / Sales38.54186.91356.3585.24Price / CashN/A65.6738.1634.64Price / Book15.315.576.233.79Net Income-$373.63M$141.67M$3.20B$247.10M7 Day Performance-4.11%-11.44%-8.32%-7.32%1 Month Performance-2.16%-14.59%-3.36%-10.20%1 Year Performance30.20%-18.30%2.72%-7.41% Madrigal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDGLMadrigal Pharmaceuticals3.4411 of 5 stars$314.39-3.9%$378.44+20.4%+33.4%$6.94B$180.13M-12.5490Positive NewsGap DownBIIBBiogen4.8404 of 5 stars$136.84-1.1%$213.33+55.9%-36.7%$20.03B$9.68B12.238,720Analyst DowngradePositive NewsUTHRUnited Therapeutics4.8566 of 5 stars$308.27+0.4%$388.25+25.9%+32.9%$13.85B$2.88B13.54980Positive NewsBMRNBioMarin Pharmaceutical4.8735 of 5 stars$70.69-1.0%$94.00+33.0%-22.2%$13.49B$2.85B32.133,401Analyst DowngradeNews CoveragePositive NewsINCYIncyte4.6061 of 5 stars$60.55-0.1%$74.88+23.7%+12.9%$11.72B$4.24B224.272,320Positive NewsNBIXNeurocrine Biosciences4.8331 of 5 stars$110.60-2.3%$165.38+49.5%-25.2%$11.03B$2.36B33.621,200Analyst ForecastNews CoveragePositive NewsGap DownEXELExelixis4.4246 of 5 stars$36.92+0.6%$37.59+1.8%+54.8%$10.33B$2.17B20.861,220Positive NewsGap DownEXASExact Sciences4.3574 of 5 stars$43.29-0.8%$70.26+62.3%-39.2%$8.04B$2.76B-7.776,400Positive NewsHALOHalozyme Therapeutics4.1259 of 5 stars$63.810.0%$62.78-1.6%+53.9%$7.88B$1.02B18.60390Positive NewsRGENRepligen4.6574 of 5 stars$127.24-4.6%$178.64+40.4%-31.4%$7.14B$634.44M-249.492,020Positive NewsGap DownALKSAlkermes4.762 of 5 stars$33.02-0.6%$39.38+19.3%+20.2%$5.37B$1.56B15.221,800Gap Down Remove Ads Related Companies and Tools Related Companies Biogen Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Incyte Competitors Neurocrine Biosciences Competitors Exelixis Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Repligen Competitors Alkermes Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDGL) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MDGL Stock Free MDGL Stock Alerts